GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Price-to-Tangible-Book

NRX Pharmaceuticals (STU:B1Q) Price-to-Tangible-Book : (As of Jun. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-06-21), NRX Pharmaceuticals's share price is €4.88. NRX Pharmaceuticals's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was €-1.65. Hence, NRX Pharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for NRX Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 4 years, NRX Pharmaceuticals's highest Price to Tangible Book Ratio was 56.66. The lowest was 1.58. And the median was 7.56.

STU:B1Q's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.6
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, NRX Pharmaceuticals's share price is €4.88. NRX Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2024 was €-1.65. Hence, NRX Pharmaceuticals's P/B Ratio of today is .


NRX Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for NRX Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Price-to-Tangible-Book Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- 14.05 9.54 -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NRX Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, NRX Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Price-to-Tangible-Book falls into.



NRX Pharmaceuticals Price-to-Tangible-Book Calculation

NRX Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=4.88/-1.652
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


NRX Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals (STU:B1Q) Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines